Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shionogi Of Japan Begins Global Foray With European Cancer Drug Trial

This article was originally published in PharmAsia News

Executive Summary

The hopes of Japan's Shionogi to launch a global molecular-targeted cancer drug got under way in Europe where the company began clinical trials. The firm's S-222611 is an oral drug of low molecular weight designed to inhibit a growth factor associated with aggressive breast cancer and a growth factor related to proliferating lung-cancer cells. Shionogi's global expansion plans rest on developing a compound to a certain stage, then either finding a development partner or licensing the drug to another company to take to market. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071178

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel